Issue 42 - Nov 6, 2020
Issue 41 - Oct 30, 2020
  • Conversation with The Cancer Letter

    Owkin’s AI model provides proof of concept that machine learning can predict gene expression across cancer types

    Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?

  • Racism is a malignancy: Ibram X. Kendi reflects on his cancer experience

    After receiving a stage 4 colon cancer diagnosis, author Ibram X. Kendi sought consultation at two hospitals located a mile apart.

  • In Brief

    • AACR 2021 annual meeting will be virtual
    • C. Ola Landgren named the inaugural leader of experimental therapeutics at Sylvester
    • Ingo Mellinghoff named chair of MSK Department of Neurology
    • Beth Gaffney named VP of U.S. and global business development at NCCN
    • Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
    • Global Cancer Institute extends programs for underserved cancer patients to Bangladesh
  • TCCL Logo

  • Trials & Tribulations

    Toward a new kind of lung cancer awareness: Addressing financial toxicity

    November is Lung Cancer Awareness Month, a time to turn our attention to an issue that already warrants our focus year-round.

  • Clinical Roundup

    • USPSTF draft guideline: Colorectal cancer screening should start at 45
    • Study: Racial disparities in treatment NSCLC persist despite gains
    • Winship study shows increased DFS rates for men with prostate cancer
    • New York Proton Center joins RadComp clinical trial evaluating proton v. photon therapy in non-metastatic breast cancer
  • Drugs & Targets

    • FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi
    • FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC
    • CPI-613 receives FDA orphan drug designation for soft tissue sarcoma
    • Exact Sciences to acquire Thrive Earlier Detection
    • EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals.
    • StrataNGS genomic profiling receives Medicare coverage in patients with advanced solid tumors
Issue 40 - Oct 23, 2020